Tauriga Sciences Inc. Commences Generating Revenue Through Product Sales on Amazon

NEW YORK, NY – (NewMediaWire) – July 14, 2021 – Tauriga Sciences, Inc.
(OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified
Life Sciences Company, today announced that it has commenced generating
revenue, through product sales on (“Amazon”), the world’s largest
online retailer.  As of July 14, 2021,
the Company has already received multiple online customer orders – via  The Company is actively
listing numerous additional products on Amazon, which should result in
increasing sales – for the remainder of this Operating Quarter (1st
Fiscal Quarter 2022) and beyond.      

In other news, the Company’s Golden
Raspberry Flavor, Vitamin D3 Infused Tauri-Gum™ product, was recently featured
in WholeFoods Magazine. 
Magazine is the leading source for
health & nutrition articles, including natural health product news.

Link to WholeFoods Magazine


Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major business activities
and initiatives.  The company manufactures and distributes several
proprietary retail products and product lines, mainly focused on the
Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market
segment.  The main product line, branded as Tauri-Gum™, consists of a
proprietary supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange,
Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant),
(Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused
Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™
Flavor: Golden Raspberry).  The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a fast-growing
E-Commerce business segment (E-Commerce website: Please
visit our corporate website, for additional information, as well as inquiries,

Complementary to the Company’s retail business, is its
ongoing Pharmaceutical Development initiative.  This relates to the
development of a proposed Pharmaceutical grade version of Tauri-Gum™, for
nausea regulation (specifically designed for the following indication: Patients
Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company
announced that it had Converted its U.S. Provisional Patent Application (filed
on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The
Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS,
the Company disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company’s clinical development efforts.

The Company is headquartered in Wappingers Falls, New
York.  In addition, the Company operates two full time E-Commerce
fulfillment centers: one located in Montgomery, Texas and the other in
Brooklyn, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking
statements” as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words such as
“may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as well as the
attainment of certain corporate goals and milestones. Forward-looking
statements are based on present circumstances and on management’s present
beliefs with respect to events that have not occurred, that may not occur, or
that may occur with different consequences or timing than those now assumed or
anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of general economic
and business conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to consummate
successful acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the “Risk Factors”
section of Tauriga’s Form 10-K and other periodic filings made from time to
time with the Securities and Exchange Commission. Such forward-looking
statements are made only as of the date of this release, and Tauriga assumes no
obligation to update forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these forward-looking




Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw


cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: 

Twitter: @SethMShaw

Corp. Website:

E-Commerce Website:

Source link

Show More

Related Articles

Back to top button